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Abstract 
Currently, there is an urgent clinical need for blood vessel replacements, 
especially in small diameter applications. Tissue engineered vascular grafts take months 
to culture and require extensive graft manipulation. The purpose of this project was to 
design a bioreactor which would output small diameter tubular and completely cellular 
vascular grafts. A cartridge was designed as a housing for five hollow, porous fibers used 
as support structures for the growth of cells seeded into the bioreactor. A pump was used 
to create a dynamic culture system and to facilitate cell seeding onto the fibers with the 
use of a vacuum force. The design was validated by analyzing the fluid flow and forces 
generated. Computer modeling and physical flow testing indicate that the bioreactor is 
suitable for cell seeding and vascular graft production. Future analysis of fiber materials 
will focus on more accurate modeling of fluid flow and assessment of cell seeding and 
vascular graft assembly. 
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1.0 Introduction  
Currently, there is an urgent clinical need for vascular grafts, especially for small 
diameter (<6mm) applications. Small diameter grafts are commonly used in arterial 
bypass surgeries and in 2005 alone, 600,000 arterial bypass surgeries were performed 
(Antman et. al., 2004). Additionally, small diameter vascular grafts are needed for 
dialysis fistulas and lower limb vessel replacements. The use of autologous grafts, tissues 
transplanted from one area in the human body to another, requires an additional surgery. 
Also, many patients lack suitable autologous vessels due to age, disease, or previous 
harvest (Schmelden et al., 2003). When suitable autologous vessels are unavailable, 
completely synthetic grafts have been used. Although these synthetic grafts may be 
suitable for large-diameter applications, synthetic grafts are highly susceptible to clotting 
when used for small diameter applications (Harbuzariu et al, 2007). There are three main 
categories for grafts including synthetic, autologous and tissue engineered.  
A number of tissue engineered grafts have been explored, but currently there is 
not an abundance of available grafts. The majority of current tissue engineering 
approaches involves the use of exogenous scaffolds, made of synthetic polymers, protein 
hydrogels, crosslinked proteins, or decellularized native tissues (Stegemann et al, 2007). 
Cells seeded into these exogenous scaffolds are cultured in vitro until suitable biological 
and mechanical function is achieved. The scaffolds are intended to provide mechanical 
support and biochemical cues so that the cells will grow into functional vessels, but there 
are many difficulties encountered by using exogenous scaffolds. The use of exogenous 
scaffolds often leads to inconsistent degradation rates, compliance mismatch between the 
old and new vessels, and a lack of biocompatibility. Although exogenous scaffolds are 
not as elaborate as cell based grafts, the complexities of these scaffolds make them 
difficult to manufacture due to their size, materials and specific surface geometry. An 
alternative approach to using exogenous scaffolds involves stimulating the cells to self 
assemble their own scaffold or extra cellular matrix (ECM) (Sun et al, 2005). In order to 
create a tissue engineered vascular graft without complications common to exogenous 
scaffolds, a graft should be developed that is completely cell-derived.  
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One company, Cytograft, uses a sheet based technology to produce completely 
tissue engineered vascular grafts. The process begins once a skin biopsy is taken from the 
patient. The human dermal fibroblasts (HDFs) are isolated using collagenase digestion, 
and the cells are allowed to culture. The HDFs are grown into cell sheets, which take six-
eight weeks to mature.  Once the sheets have been grown, they are rolled four times 
around a stainless steel cylinder with an outer diameter of 4.75 mm. The sheets are then 
cultured for 12 weeks to allow the layers to fuse together while air drying in a tissue 
culture hood to form an acellular internal membrane. Additional living fibroblasts sheets 
are then wrapped around this structure four times and matured for an additional six-eight 
weeks. The resulting structures are then available for in vivo use. Currently these vessels 
are in clinical trials as dialysis fistulas (Konig, 2009) While the clinical trials are 
promising, this method is lengthy with an overall process totaling up to 28 weeks 
(McAllister, 2006). 
While the method used to create vascular grafts is crucial, the system and 
bioreactor the tissue is grown in is also important.  The state of the art for creating a 
completely cell-derived vascular graft requires manipulation of the tissue and is very time 
consuming.  The current methods also use the traditional method of growing cells on a 
flat plate, where they grow and divide naturally with ease.  Creating a bioreactor that can 
produce cylindrical vascular grafts could essentially remove manual rolling steps, 
therefore eliminating the time it takes to produce these grafts and contamination risks.  
The proposed bioreactor aims to culture cells to self-assemble into vascular grafts, a 
difficult change in itself. A bioreactor that is inexpensive to manufacture is also needed to 
save on the large costs spent on the research using blood vessels. The bioreactor has the 
potential to create grafts that could be used to eliminate painful surgeries associated with 
using autologous grafts as well as the complications associated with using synthetic 
grafts.  Since the tissue engineered vessels use autologous cells, the biocompatibility risks 
may be minimized are irrelevant. With proper conditioning, the correct mechanical 
properties could be produced, unlike current technology with synthetic grafts. 
Therefore, the goal of this project is to design, build and develop a method for a 
bioreactor to facilitate cell assembly into blood vessels without the use of exogenous 
scaffolds. The bioreactor should also minimize cell and tissue manipulation so that the 
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vessels can be produced both quickly and easily. The completely biological vascular 
grafts should be approximately 2mm in diameter, 5cm in length, and 250 µm in wall 
thickness, consequently the bioreactor should be designed to fulfill these requirements. 
Designing and building a bioreactor that could use a patient’s own cells to produce 
multiple grafts would allow for testing of the grafts to make sure they are ready to be 
implanted.  Since it is likely not all the grown vessels would be necessary for graft 
replacement, any additional could be used to test the properties.  Multiple graft 
reproduction is also important for the research standpoint, where different aspects of the 
graft would be investigated requiring multiple grafts to be tested.  The bioreactor should 
also be adaptable for different size specifications that may be required in the future. 
In order to design and build a bioreactor there were certain steps that needed to be 
completed to verify that the design fits the desired outcomes the most effectively. The 
design method that was used was a five step process revised from Engineering Design: A 
Project-Based Introduction written by Clive Dym and Patrick Little.  The steps were 
based on the initial client statement from which the problem definition, conceptual 
design, preliminary design, detailed design, and design communication led to the final 
design.  
The first stage, the problem definition, took the client statement to first clarify the 
design objectives, establish the user requirements and functions and to identify the 
constraints.  The revised client statement, objectives, constraints, user requirements and 
functions, which will be described later in Chapter 3.0, were established next.  The design 
specifications and design alternatives were used to generate the conceptual designs, 
which had several aspects, including a mandrel to seed cells on, a method to seed the 
cells and a system to grow the cells in.  During the preliminary design stage, which was 
the stage that a final design was chosen, testing and evaluation of the results were 
completed to determine which aspects would be included in the final design.  During the 
fourth stage, the detailed design, the final design was refined based on testing and the 
proposed fabrication specifications were determined.  Ultimately, the fifth and final stage 
was the design communication stage in which the design was documented and submitted 
to the client.   
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Prior to the design stages, related topics were researched in order to understand 
the client statement and define it more clearly. An in-depth patent search was also 
conducted in order to ensure that the design was original and no similar devise had been 
patented. Sections of the paper were also included to describe the effects the project may 
have on aspects such as the environment and the economy. Finally, future 
recommendations were made so that improvements can be made to the design in the 
future based on the results and conclusions that were determined. 
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2.0 Literature Review  
Small-diameter graft replacements have become increasingly essential in recent 
years as hospital stays and the money spent on Coronary Heart Disease (CHD) has 
increased significantly (Shaw, 2006). Although synthetic and autologous grafts have 
proven to be adequate, there is a growing need for a completely cell derived small-
diameter vascular grafts to minimize complications and reduce costs. Clinical trials have 
proven that completely cell derived small-diameter vascular grafts have minimal side 
effects and complications that have been common in patients with synthetic grafts 
(McAllister, 2006). 
 
2.1 Coronary Heart Disease 
Coronary Heart Disease, affecting the vasculature of the heart, was the cause of 
one out of every five deaths in the U.S. year 2005 (National Center for Health Statistics, 
2005). Nearly 450,000 Americans died from the disease in the year 2005. A higher 
proportion of men have cardiovascular disease than women, one in six women have the 
disease. In 2005, the disease accounted for one out of every 2.7 deaths for women 
(National Center for Health Statistics, 1979-2005). While life style choices have been 
shown to increase or decrease the risk of developing coronary heart disease, many 
Americans also inherit genes that increase their risk (Stampfer et al, 2000). 
An estimated 8 million Americans have had a myocardial infarction, out of a total 
of almost 17 million Americans that have been diagnosed with at least one type of 
coronary heart disease (Lloyd-Jones et al, 2009). Myocardial infarction is a common 
result of coronary heart disease. Infarct occurs when a blockage in the coronary artery 
cuts off blood flow to part of the heart. The resulting blockage can lead to the death of the 
distal heart tissue.  In order to repair this condition, a common solution is to use a 
coronary artery bypass graft (CABG), which bypasses the blockage and restores blood 
flow to the affected tissue, as seen in Fig. 2.1. Small diameter vascular grafts are used in 
patients with coronary heart disease to bypass blockages in the coronary arteries and 
restore blood flow to the heart. 
6 
 
Figure 2.1: Coronary Artery Bypass Graft 
Found at: http://www.nlm.nih.gov/medlineplus/ency/presentations/100190_1.htm 
The American Heart Association estimated that in the year 2009, CHD would be 
responsible for over 750,000 American deaths and over 450,000 recurrent attacks  
(Heron, 2008). Additionally, it is estimated that every minute an American will die 
from a coronary event and every 25 seconds someone will have a heart attack. Due to the 
relevance of CHD and myocardial infarction, there is a significant clinical need for 
vascular grafts in order to facilitate CABG procedures. As explained in the following 
sections, current sources of vascular grafts for CABG and other procedures are often not 
ideal or even adequate.  
 
2.2 Physiology and Mechanics of Blood Vessels 
Understanding the physiology and mechanics of blood vessels is a necessary step 
in developing graft replacements. Vascular tissue is composed of cells supported by 
extracellular matrix ECM. Blood vessels consist of three main layers. The outermost 
layer is the tunica adventitia, composed of a tough collagen fiber layer which provides 
tensile strength. The adventitia tends to be thicker in arteries than in the corresponding 
veins.  The middle layer is the tunica media. This is primarily composed of smooth 
(involuntary) muscle cells (SMCs) and elastic fibers. Cells and fibers composing this 
layer are oriented circumferentially as seen in Fig 2.2.  
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Figure 2.2: Structure of a Medium-Sized Blood Vessel 
(Stegemann, 2007) 
 
The tunica media is primarily responsible for physiological responses. This layer 
is much thicker in arteries due to the pulsatile nature of the blood pumping and higher 
pressures in these vessels. Since arteries receive blood from the heart, the pulses are 
stronger, while the pulsatile flow in veins has been diminished after passing through 
capillaries. Therefore, the arterial walls need to be stronger. The innermost layer is the 
tunica intima, composed of an endothelial monolayer separated from the tunica media by 
the sub-endothelial ECM layer. The intima provides crucial anti-thrombogenic properties 
in the lumen and is a selectively permeable barrier between the blood and the rest of the 
body.  Elastic lamellae exist between both the adventitia and the media, and the media 
and the intima. The elastic lamellae thicknesses vary depending on vessel type and are 
primarily responsible for elastic recoil. It is likely that the intricate nature of native blood 
vessels need not be precisely replicated in order to generate clinically successful vascular 
grafts.  Research has primarily focused on achieving vascular grafts with suitable 
compliance, biocompatibility, burst pressure, and anti-thrombogenic properties (Mitchell 
and Niklason, 2003). 
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2.3 Graft Replacement Sources 
There are three main sources of grafts, autologous, synthetic and tissue 
engineered grafts. Although current technology is limited, solutions have been realized in 
each of these categories. 
 
2.3.1 Autologous Grafts 
In 2005 alone, 600,000 arterial bypass surgeries were performed with autologous 
grafts (Kielty et al., 2007). The two main sources of autografts for bypass are the Left 
Internal Mammary Artery and the Greater Saphenous Vein as seen in Fig. 2.3. The 
benefits of using autologous grafts are that there is no risk of rejection or immune 
response, and that they are completely natural vessels with functional non-thrombogenic 
endothelial monolayers. The use of these grafts involves additional surgery, although 
patients may lack suitable autologous vessels due to age, disease, or previous harvest 
(Schmelden et al., 2003). Veins used in place of arteries can also suffer compliance 
mismatch and insufficient mechanical strength. The additional risks and pain involved 
with the harvest surgery and the lack of suitable donor vessels in some patients creates a 
need for alternative graft sources in many situations.  
 
Figure 2.3: Autologous Graft Replacement 
Found at: http://www.nlm.nih.gov/medlineplus/ency/presentations/100190_1.htm 
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2.3.2 Synthetic Grafts 
 When suitable autologous vessels are unavailable, completely synthetic grafts 
have been used, pictured in Fig. 2.4. Dacron and ePTFE are the main materials used in 
synthetic vascular grafts today (Ratner et al., 2004). In small diameter applications, these 
synthetic grafts are highly susceptible to clotting and failure due to a lack of a conFluent 
non-thrombogenic endothelial monolayer. Upon implantation, the luminal surface of the 
synthetic graft is coated with plasma proteins, and eventually a platlet-fibrin aggregate 
(pseudointima). This is then covered with an endothelial layer, but only in a 10-15 mm 
zone from the anastomosis. The pseudointima that is not endotheliazed can be subjected 
to SMC migration and proliferation leading to intimal hyperplasia, or trigger clot 
formation and thrombosis. Fibrous hyperplasia caused by an over active physiological 
repair response at the anastomic site also often leads to failure of the grafts. 
 
Figure 2.4: Synthetic Graft Replacement 
Found at: http://www.atsmedical.com/uploadedImages/Public_Site/Products/Mechanical_ 
Valves/BI1-1_avg.jpg 
 
2.3.3 Tissue Engineered Grafts 
The most common tissue engineering approach involves the use of exogenous 
scaffolds into which cells are seeded and cultured. These scaffolds provide structural 
support and allow for cell growth, migration, differentiation and cellular ECM 
production. Ideally, these scaffolds would degrade at the same rate as the natural tissue 
would proliferate and synthesize ECM. Tissue engineering scaffolds can be composed of 
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either natural or synthetic materials. An example of a tissue engineered graft is shown 
below in Fig. 2.5. 
 
Figure 2.5: Lifeline Graft 
Found at: http://cytograft.com/technology.html 
 
2.3.3.1 Synthetic scaffolds 
Synthetic scaffolds can be created from a variety of polymers such as polyesters, 
polyanhydrides, and polyphosphazenes (Yoon and Fischer, 2006). The initial chemicals 
and reactions necessary to synthesize these polymer scaffolds are incompatible with cell 
survival. Therefore the cells cannot be incorporated directly into the polymer scaffolds as 
they are formed. Instead cells must be seeded into the completed scaffolds posing 
difficulties in achieving uniform cell distribution and attachment. The scaffold 
degradation rate must be equal to the cellular proliferation rates and ECM synthesis in 
order to maintain graft structure and mechanical properties, and to avoid failure. 
Polyglycolic acid (PGA) and Polylactic co-glycolic acid (PLGA) are most commonly 
used as tissue engineering scaffold but are both resorbed rapidly (Isenberg et.al., 2006).  
It has been found that tailoring polymer scaffold degradation rates to correspond with 
varying cellular proliferation rates and ECM synthesis, while maintaining 
biocompatibility, poses a considerable challenge (Nerem and Ensley, 2004).   
Although synthetic scaffolds provide initial mechanical strength and structure, 
compliance mismatch with native vessels has proven difficult to overcome (L’Heureux 
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et. al., 2006). This is due to the inability to match the mechanical properties of native 
vessels with synthetic vessels, which result in low compliance between the native tissue 
and graft. Thrombosis can result when mismatch between the mechanical properties of 
the native tissue and replacement occurs. Compliance mismatch quickly leads to the 
failure of implanted grafts due to the stresses of repetitive cyclic loading, which occurs 
when blood is continuously pumped through the vessel. The compliance of vascular 
grafts once the scaffold has resorbed is the result of cell generated ECM (Heydarkhan-
Hagvall et. al., 2006). However, it has been shown that ECM production is inhibited in 
cells that are in contact with synthetic polymers (Nerem and Ensley, 2004).  This finding 
has led many researchers to investigate alternatives to synthetic polymer scaffolds. 
 
2.3.3.2 Natural Scaffolds 
  Natural protein scaffolds utilize the components of native ECM and create fully 
biological grafts. Natural protein scaffolds can be composed of collagen, elastin, 
fibronectin, or protein hydrogels (Stegemann et al, 2007). However, these scaffolds do 
not provide sufficient initial mechanical strength to support normal hemodynamic loading 
(Zhang et al, 2007). To improve mechanical properties and increase collagen fiber 
alignment, cross-linking has been increased and mechanical conditioning has been 
applied in vivo (Nerem and Ensley, 2004). Additionally, natural protein scaffolds are 
often difficult and expensive to manufacture (Stegemann et al, 2007). 
Decellularized tissues are also used as scaffolds, composed of natural ECM, and 
as such offer improved biocompatibility. Animals can be used as a tissue source with the 
benefit of being readily available and inexpensive. The chemical processes through which 
the tissues are decellularized however, negatively affect the mechanical properties 
(Swartz et al, 2005). Chemical cross-linking is then required in order to attempt to restore 
suitable mechanical properties, which have yet to be tested I complex and risky situations 
such as a bypass-application (Stegemann et al, 2007).  
 
2.3.3.3 Cell-Derived Vascular Grafts (No Exogenous Scaffolds) 
Researchers are developing alternative approaches that avoid the use of 
exogenous scaffolds. By creating completely biological vascular grafts without the use of 
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exogenous scaffolds, it is likely that compliance match can be more easily achieved 
(Swartz et al, 2005). This approach requires that the cells synthesize their own 
ECM/scaffold. ECM production in cells can be stimulated through surface topography, 
chemical signaling, and mechanical conditioning (Swartz et al, 2005).  
Cell sheets have been cultured and utilized to create layered vascular grafts. 
Monolayers of fibroblasts and SMCs have been cultured in medium enriched with 
ascorbic acid in order to stimulate production of collagen type I. The resulting vessels 
have high burst strengths of 2000 mmHg and perform well in suture pull out tests 
(L’Heureux et al, 2006). These collagen-rich cell sheets can be removed from the 
culturing surface without damage, which is essential. Multiple sheets are wrapped around 
a mandrel in order to form a tubular graft. Such grafts have recently been approved for 
use in clinical trials in blood vessel access applications (L’Heureux et al, 2006).  
Cytograft Tissue Engineering, in late 2008, reported results from their first 
clinical trial using sheet-based tissue engineered vessels (Konig et al., 2008). The multi-
ply graft can be seeded with endothelial cells to produce a completely autologous tissue 
engineered blood vessel named Lifeline
TM
. The cells for these clinical trials were sourced 
from patients with end-stage renal disease, lower-limb ischemia, or coronary artary 
disease, 25 patients in total. The engineered blood vessels were compared to native 
human vessels in patients with advanced cardiovascular disease in burst pressure, fatigue 
resistance with static or dynamic loading, suture retention strength, and compliance tests. 
This was the first demonstration of completely biological tissue engineered blood vessels 
implanted in humans (Konig et al, 2008). The vessels were implanted as either an arterio-
venous shunt for dialysis purposes, or a lower-limb bypass, which have greater failure 
rates than upper-body replacements due to increased pressure. The results from this 
clinical trial provide benchmarks for future cardiovascular tissue engineering studies 
(Konig et al, 2008). 
L’Heureux and his research team have been largely responsible for the success of 
vascular grafts generated through the utilization of cultured cell sheets. High patency and 
anti-thrombogenicity have been achieved in animal and human models with these grafts. 
Lengthy production times are required with these techniques however, and greatly hinder 
clinical implementation. Additionally, the over expression of collagen necessary to make 
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the grafts easy to handle, results in compliance mismatch and overly stiff grafts (Swartz 
et al, 2005). 
 
2.4 Patents 
An in-depth patent search was conducted to find completely tissue-engineered 
vascular grafts.  Although there are similar patents using scaffolds and manipulated 
grafts, there is currently only one patent for a completely tissue-engineered vascular graft.  
Two patents and one patent application were found through the U.S. Patent and 
Trademark Office. The patents and applications were found to be the only ones that 
claimed to be able to produce completely scaffold free, cell derived tissue engineered 
grafts. 
 
2.4.1 Patent # US 7,112,218 B2 
Todd McAllister and Nicolas L’Heureux filed patent# US 7,112,218 B2 on 
September 26, 2006. This was for a bioreactor with mechanisms to grow tissue sheets and 
a rolling mandrel for the sheets to wrap around. This allows tissue sheets to be grown and 
then concentrically wrapped around a mandrel in order to create autologous blood vessels 
with little handling as seen in Fig. 2.6. There is a clamp for holding the sheet to the 
mandrel while wrapping the tissue. Fibroblasts are isolated from a skin biopsy, and 
cultured into a sheet. A supplementary rod with a control blade that rotates toward the 
sheet is used in order to separate 1-3 cm of the sheet’s leading edge. This separated 
portion is then draped over the rollable mandrel. A magnetic clamp holds the tissue sheet 
to the mandrel, and remains in the roll to be taken out later. A Teflon coating over the 
mandrel prevents cell adhesion. Once the tubular vessel has matured, the cells are 
denatured. A cell sheet of fibroblasts is rolled over the denatured vessel. A suspension of 
endothelial cells is then placed in the lumen of the vessel to seed the lining. These vessels 
can be directly grafted into the patient or can be further conditioned mechanically with 
hemodynamic forces (McAllister et al, 2006). 
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Figure 2.6 Rolling Mandrel (McAllister et al, 2006) 
 
2.4.2 Patent # US 20,060,240,061 A1 
Atala et al. of Wake Forest University developed a method utilizing a matrix 
seeded with endothelial cells, as stated in application US 20,060,240,061 A1. A 
biocompatible matrix is seeded with endothelial cells and there is a chamber that 
preconditions the matrix by moving biological fluid through the inner surface. This is a 
continuous flow that can be adjusted to control shear stresses in the vessel wall. Pulse 
rates and pressures are also adjusted to condition the tubes. The exterior can be pre-
conditioned with this device by filling the preconditioning chamber with biological fluid. 
Therapeutic agents such as heparin can also be incorporated into the scaffolds. The 
scaffolds were created using electrospun fibers to allow greater flexibility and the 
creation of custom shapes. Teflon was also used in order to reduce cell adherence to the 
mold (Atala et al, 2006). 
 
2.4.3 Patent Application # US 20,070,128,171 
Another patent for tissue engineered blood vessels was completed by Tranquillo, 
Fig. 2.7, depicts the proposed blood vessel. Tranquillo developed a method to create 
engineered blood vessels which include an intimal layer surrounded by a smooth muscle 
media layer which are constructed around a tubular support.  A matrix of endothelial cells 
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and smooth muscle cells form a bi-layer.  This bi-layer forms a tubular structure around a 
support which is permeable to attractant factors. The application states that the formation 
of endothelial intimal layers should be surrounded by a smooth muscle medial layer, 
following the protocol that was conducted. 
 
Figure 2.7: Drawing of Tranquillo's Layered Tissue Engineered Blood Vessel 
 
2.5 Gaps in Current Technology 
As previously discussed, current technology is lacking a suitable small diameter 
blood vessel replacement. The primary source for small diameter graft replacements is 
the autologous vessel, which requires a second surgery. The second surgery increases the 
risk of infection, pain from the operation and lengthens surgery time. Out of the 785,000 
Americans who have a myocardial infarction, 470,000 are estimated to have recurrent 
attacks. These patients have a continued heart disease, as well as previously harvested 
vessels, making the resources for second surgeries limited (Lloyd-Jones et al, 2009). 
Coronary heart disease is estimated to cost $165.4 billion annually through direct and 
indirect costs. Tissue engineered blood vessels for coronary bypass would greatly impact 
the state of the art and is only one possible application for these grafts. Implanting grafts 
as a dialysis fistula and replacing any vessel in the body, especially lower limb vessels, 
are other applications of a completely tissue engineered vessel.  
The Cytograft technology is innovative and shows great promise for tissue 
engineering grafts. The task of completely cell-derived grafts is achieved, but the 
resulting grafts take about 6 months to produce, a very impractical timeline. Additionally, 
the clinical data was recently released, showing the results of several mechanical tests. 
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The Lifeline vessel replacement was compared to internal mammary arteries, and the 
results were drastically different in cases such as burst pressure and compliance. A native 
internal mammary artery has a burst pressure of 1599±877 mmHg while the Cytograft 
vessel ranged from 3399-3523 mmHg, nearly triple. For compliance, the native vessel 
was 11.5%100/mmHg while Cytograft was 3.4%/100mmHg, showing that the engineered 
tissue was much stiffer (Konig et al, 2008). While these vessels show promise and 
successful in vivo testing, there are still issues with mechanical properties that need to be 
addressed during culture.  
Synthetic vessels work well in large diameter vessel replacements, such as aortic 
aneurysms, but can cause clots in small diameter applications. The immune response 
elicited from implanting a polymer and the lack of anti-thrombogenic endothelial cells 
make these ineffective in bypassing surgeries. The mechanical properties of synthetic 
grafts are also different enough to cause problems. Using tissue-engineered vessels can 
eliminate the immune response as well as eventually lead to closer mechanical properties 
to native tissue.  
The bioreactor design itself is a great opportunity to address two large problems: 
mechanical properties by having cells self-assemble into the vessel geometry and cut 
down the growth time of tissue-engineered vessels. By using a cylindrical mandrel and a 
method having cells culture in the natural assembly of blood vessels, the current 
problems related to tissue engineered grafts may be eliminated. Cell alignment is crucial 
to the strength and properties of the vessels and the assembly process can influence the 
cell growth direction. Also, a bioreactor that facilitates self-assembly will reduce 
manipulation and culture time for layers to fuse after growing in sheets. The idea that 
cells can be put into a bioreactor and after a culture period, a blood vessel may be 
removed is the ultimate goal of this project. The approach of this project is to create a 
whole system that will enable sterile cell culture and growth of tissue engineered vessels, 
eliminating production time and potential for user error or concern. 
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3. 0 Project Strategy  
The design of a bioreactor to facilitate cell-derived vascular grafts was motivated 
by the need for small diameter vascular replacements. Throughout the design process the 
client’s needs were assessed in order to direct the development of the project. In order to 
meet the client’s expectations, interviews were conducted resulting in a client statement. 
From here, design objectives, functions, specifications, and constraints were established. 
Various design methods were utilized to further clarify the goals of the project.  These 
methods included pairwise comparison charts, objective trees, and functions-means trees 
were used to guide the development of the design. 
 
3.1 Initial Client Statement  
Weekly interviews were conducted with our client and advisor, Dr. Marsha Rolle. 
In these meetings, the need for small diameter vascular replacements and the problems 
associated with current vascular graft designs were presented and discussed. The client’s 
initial desires for the design were outlined in the initial client statement:   
The goal of this project is to design a bioreactor to 1) 
generate totally biological vascular grafts by cellular self 
assembly into tubular structures (in the absence of 
exogenous scaffolds and cell sheets) and 2) support sterile 
culture and conditioning of the resulting vascular grafts. 
The ultimate goal of the project is to create a device that 
will reproducibly generate tissue engineered blood vessels 
with physiological and mechanical properties suitable for 
transplantation.  
 
 The above client statement was expanded and revised as interviews continued and 
as sufficient background research was conducted.  
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3.2 Objectives & Constraints  
Key goals of the project were determined from the revised client statement and 
expanded into a complete list of objectives and constraints. The list was split into 
objectives for the bioreactor design and objectives for the vascular grafts. Pairwise 
comparison charts (located in Appendix A) were used to weigh the importance of each 
objective and constraint.  The objectives were broken further into sub-objectives and both 
were compiled in an objectives tree shown in Fig. 3.1 and 3.2. 
 
3.2.1 Bioreactor 
 After an in-depth discussion on what features, attributes and functions the 
bioreactor should satisfy, objectives and constraints for the bioreactor were determined. 
In order to fulfill the client statement, the bioreactor was designed to produce tissue in a 
cylindrical form so that no tissue manipulation is required to produce a graft. Not only 
should this bioreactor produce grafts quickly, it should also be easy to use, safe and 
provide a continuous nutrient delivery. Finally, the bioreactor should be able to produce 
more than one tissue tube at a time and should be inexpensive to produce and grow the 
grafts. Objectives of the bioreactor are shown in Fig. 3.1.   
 
Figure 3.1: Bioreactor Objectives 
There were also numerous constraints that needed to be taken into consideration 
when designing the bioreactor.  Time and budget were driving constraints; the project 
needed to be completed with a budget of $624.00 and by April 30
th
, 2009. The facility 
used to create the bioreactor was also a constraint because the project was completed in 
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an assigned lab area in Salisbury Laboratories at Worcester Polytechnic Institute. Space 
was limited and the bioreactor needed to fit within the allotted space in the incubator.  
 
3.2.2 Vascular Grafts 
In order to design and build a bioreactor, it was also important to keep in mind the 
desired objectives for the vascular grafts that would be produced by the bioreactor. The 
bioreactor should be able to produce vascular grafts in a manner that is reproducible, so 
that not only each graft is the same, but also so that the bioreactor produces the same cell 
derived graft each time it is used. The design should also incorporate a way to influence 
the grafts to self generate Extracellular Matrix (ECM). When the bioreactor has produced 
vascular grafts, these grafts should also be suturable, easy to handle and should be able to 
withstand the pressures of a natural tissue which is around 1599 ± 877 mmHg (Konig et 
al, 2008).  
 
Figure 3.2: Vascular Graft Objectives 
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3.3 Revised Client Statement  
A revised client statement was developed through determining the objectives and 
constraints of the project. The revised client statement is as follows:  
The goal of this project is to develop a method to quickly 
generate multiple vascular grafts through the design of a 
novel bioreactor. The method and design should stimulate 
self assembly of cells introduced to the bioreactor, without 
the use of exogenous scaffolds. The design should produce 
reproducible tubular grafts that have self generated 
extracellular matrix. Additionally, the necessity for graft 
manipulation should be minimized so that the vessels are 
produced quickly and easily. The completely biological 
vascular grafts should be approximately 2 mm in diameter, 
5 cm in length, and 250 µm in wall thickness. The resulting 
grafts should be suitable for transplantation: sutureable, 
easy for surgeons to handle, strong enough to withstand 
pulsatile flow and biocompatible with the recipient. 
 
3.4 Needs Analysis  
In order to determine which objectives were most important, a pairwise 
comparison was used and can be found in Appendix A. Scores were given based on 
conversations with the client and calculated appropriately. Needs and wants of the design 
were narrowed down based on scoring. This weighted objective tree for the objectives of 
the bioreactor is shown in Fig. 3.3. The safety objective was eliminated from the tree as it 
is always considered throughout the process and was deemed the most important by the 
client. Through additional conversations with the client it was determined that developing 
and validating the bioreactor design was the main objective of the project, which was 
continued throughout the remaining portion of the project.  
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Figure 3.3: Weighted Objective Tree based on needs analysis 
3.5 Bioreactor Functions 
 In order to meet the objectives of the bioreactor, desired functions of the 
bioreactor were split into three main categories. The categories and the functions of the 
bioreactor are listed in Table 3.1. The design of the bioreactor consisted of determining 
the best structure to assemble the cells, the method to assemble and culture cells and the 
housing to culture and monitor tissue. 
Table 3.1: Bioreactor Functions 
Functions of Bioreactor 
Structure to Assemble the Cells  
 
Creates/Supports  tubular construct 
 
Allow removal of intact tubular 
construct 
Method to Assemble and Culture Cells  
 
Facilitate cell seeding 
 
Promote cellular growth 
 
Promote cell adhesion 
Housing to Culture and Monitor Tissue  
 
Allow nutrient diffusion/ gas exchange 
 
Allow for visualization of fibers 
 
Housing for fibers 
 
Fixation of Fibers 
 
Vacuum adheres cells to mandrel 
 
Closed off housing 
 
Fibers are easily removed 
Bioreactor 
Design
Generate tubular 
construct
26 %
Fast graft 
generation
18%
Continuous 
nutrient delivery
10%
Easy to use
15 %
Multiple cultures
0%
Low cost
0%
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3.6 Project Approach  
Once the functions of the bioreactor were clearly established, the design of the 
bioreactor began in three distinct categories to be designed and verified. These three 
design categories were examined and analyzed in parallel to determine the optimal means 
to create the bioreactor as seen in the morphological chart in Appendix B and design 
matrixes in Appendix C. As pictured in Fig. 3.4, the bioreactor functions were split up 
into three main categories which were; structure to assemble cells, method to assemble 
and culture cells and a housing to culture and monitor tissue. Each of these three 
categories were investigated in Chapter 4 and later verified in Chapter 5. 
 
Figure 3.4: Three Function Groups of Bioreactor 
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4.0 Alternative Designs  
Once the project objectives were weighted by importance in designing the 
bioreactor, conceptual designs were generated. Through initial brainstorming, functions 
were developed and it was decided that cells would need a surface to adhere to in order to 
meet confluence and create a tubular structure. With the functions in mind, different 
designs were investigated to meet the functions and objectives of the bioreactor. 
Additional components were added to a traditional bioreactor to promote cell growth and 
cell seeding. A custom cartridge in which to culture the vascular grafts would be 
necessary.  The compiled functions helped in creating an overall schematic of how the 
bioreactor would be assembled, which is shown in Fig. 4.1.  
 
Figure 4.1: Bioreactor Schematic 
The conceptual designs were chosen with the functions in mind. Controlling the 
cells as they grow eliminated the step of manually rolling sheets of tissues into tubes, 
which is currently a critical step in tissue engineered grafts  
 
4. 1 Structure to Assemble Cells 
 The first function category that was investigated was the structure to assemble the 
cells on, the schematic depicted in Fig. 4.2. The options were split up into a group of 
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cylindrical mandrels upon which to culture the cells a mechanical mandrel idea, which 
would allow for flat cell growth and a porous mandrel idea which would allow for 
nutrient diffusion. 
 
Figure 4.2: Structure to Assemble Cells 
 
4.1.1 Mandrel Designs 
    In order to culture cells directly into tubular structures, four main design 
categories were developed. These four design categories all involved the use of tubular 
forms or mandrels upon which the cells would be directly cultured and self assembled 
into tubular vessels. The first design category utilizes a cylindrical mandrel the size of the 
inside diameter of the required vessel and can be seen in Fig. 4.3. The cells could be 
cultured into a vascular graft around the outer surface of the mandrel.  
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Figure 4.3: Mandrel Designs 
 
The second category would utilize a tubular dye. Cells could be cultured on the 
inner surface of the dye, as seen in the Fig. 4.3. The dye would have an inside diameter 
equal in size to the outside diameter of the required vascular graft.   
The third design, as pictured in Fig. 4.3, would allow for cell culture around an 
outer diameter, equal in size to the desired inner diameter of the vascular graft. One 
option for a hollow mandrel that was investigated in depth was hollow fibers, which are 
used in filtration cartridges and hollow fiber bioreactors.  Hollow fiber bioreactors, as 
seen in Fig. 4.4, create an artificial capillary system in a cartridge so that higher cell 
densities and proliferation rates can be achieved as compared to standard flask or plate 
culture techniques. Fibercell Systems Inc. produces a hollow fiber bioreactor with fibers 
that are 1.3 mm in outside diameter.   
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Figure 4.4: FiberCell Cartridge 
 
Media circulating through the porous hollow fibers delivers glucose, oxygen, and 
nutrients to the cells, and at the same time carries metabolic waste products as seen in 
Fig. 4.5. Media flow through the porous hollow fibers also ensures that cells attached to 
the mandrel receive the same nutrient diffusion from inside and outside the fibers as the 
cells interacting with the media inside the main cartridge.  
 
Figure 4.5: Oxygen, Nutrient and Waste Flow through Fibers 
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The fourth and final design category, as seen in Fig. 4.3, would utilize a mold in 
which the vascular graft would be cultured. The negative space created by the mold 
would be the size of the required vascular graft. This mold would also control the wall 
thickness of the graft by establishing both the inside and outside diameters. The negative 
space mold approach constrains the cells within a space such that the cells needn’t 
necessarily attach to the surface. This design was similar to a conventional negative space 
mold. The challenge in this design was to keep the cells dispersed throughout the mold, 
as the force of gravity would naturally draw them all to the bottom. By rotating and or 
vibrating the mold in various directions it could be possible to keep a media and cell 
solution evenly distributed throughout the mold until the cells proliferate sufficiently to 
form a unified tubular construct. 
 These approaches require some method of maintaining the cells on the surface of 
the die or mandrel in opposition to the force of gravity. Until the cells attach sufficiently 
to the surface, or confluence is reached and cell to cell attachment is sufficient, gravity 
will prevent cells from maintaining contact with the surface of the die or mandrel. This 
problem would not be encountered in cell sheet culture as gravity keeps the cells arranged 
on the flat surface upon which the sheets are cultured.   
 
4.1.2 Mechanical Mandrel 
As an alternative to using a mandrel that is initially tubular, the possibility of 
using a structure that was initially flat was also considered. This would allow the cells to 
be easily seeded and cultured into sheets, since cells are commonly grown on a flat dish. 
Once the cells reached confluence or sufficient cellular attachment to the structures 
surface was achieved, the structure could roll up into either a tubular die or mandrel. A 
close view of the flat roll-able mandrel can be seen in Fig. 4.6.  
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Figure 4.6: Flat Mandrel before Rolling 
The cells could then be further cultured into the final tubular construct, as seen in 
Fig. 4.7, by allowing the cells to proliferate until the seam between the two ends of the 
sheet were fused and the appropriate wall thickness was achieved. These mechanical 
mandrels or dyes would be made of a flexible culture surface or membrane, attached to a 
mechanical, segmented structure.  
 
Figure 4.7: Mechanical Mandrel Rolled 
 The mechanical mandrels or dies investigated fell into two categories. The first 
involved the use of multi-component mechanical assemblies that could easily convert 
from flat to tubular structures. These mechanical dies or mandrels would have to create 
inside or outside graft diameters of only a few millimeters.  The second category of 
mechanical die or mandrel involved the use a shape memory alloy such as nitinol. This 
could eliminate the need for complex multi component structures, since these shape 
memory alloys can convert from one shape to another based on temperature changes or 
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other external stimuli. A flat membrane could be lined with simple nitinol bands that 
could alternate between flat bands and round hoops, thus creating a construct that 
transforms from a flat into a tubular structure when the appropriate external stimulus was 
applied. 
 
4.2 Method to Assemble and Culture Cells 
 The second design function that was investigated was the method to assemble and 
culture the cells on. The selection of the method was also determined by the structure to 
assemble the cells. Four methods to seed the cells onto a mandrel were investigated.  
Static seeding, a method to manually rotate the cartridge, and an automated rotation 
system and a pump/vacuum system led to the final decision, which was determined 
through design verification. This design function is highlighted from the overall 
schematic in Fig. 4.8. 
 
Figure 4.8: Method to Assemble and Culture Cells 
 
4.2.1 Static Seeding 
 The simplest seeding method would be a static seeding method in which the cells 
would be seeded into the chosen housing of the bioreactor.  In the case that a mechanical 
mandrel was used, static seeding would be an option. Static seeding is a common method 
in which cells are simply placed in a flask and allowed to grow into cell sheets.  
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4.2.2 Manual Rotation 
Avoiding the use of cell sheets and mechanical mandrels would be achieved by 
allowing the cells to attach in series to a slowly rotating mandrel or dye surface.  
Sufficient attachment strength would need to be achieved before the surface was rotated 
such that gravity opposes the cell to surface attachment. This would have required a very 
slow rate of rotation and perhaps an equally slow introduction of cell suspension to 
prevent cell aggregates from forming instead of cell to surface binding.  
 
4.2.3 Automated Rotation System 
 An automated rotation system would have eliminated the need to manual rotate 
the cells and could be controlled. This would have been able to eliminate the uncertainty 
involved in manually rotating cells for a specified time and would also eliminate the 
manual work required, better meeting the objectives of the bioreactor. 
 
4.2.4 Pump/Vacuum System 
Another possible method for maintaining the cells on the surface of a mandrel, 
involved the creation of a vacuum at the surface resulting from an inward flow of media. 
This flow would maintain the cells on the surface until they attach to the surface or 
proliferate sufficiently to aggregate and provide their own mechanical support, Fig. 4.9. 
The use of a porous construct would be required so that media could be drawn through 
the surface to create a vacuum. Media flow could also provide nutrient and gas exchange 
and thus provide biological support as well as mechanical support.   
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Figure 4.9: Cell Attachment to Surface 
 
4.3 Housing to Culture and Monitor Tissue 
 The third function of the bioreactor was an essential step in developing bringing 
each of the components together. It was necessary to take into account each of the 
objectives, constraints and functions in order to produce this central piece of the system.  
Design alternatives for the cartridge were generated using a morphological chart located 
in Appendix B and qualified using a decision matrix found in Appendix C.  The housing 
to culture and monitor tissue, Fig 4.10, was designed to allow constructs to be easily 
removed and installed, cells to be seeded directly into the cartridge and to accommodate 
multiple cultures. Additionally the design was expanded to allow for housing, fixation, 
and visualization of the cultures and facilitation of cell dispersion during seeding. 
Additionally the design of the cartridge should incorporate a material that should inhibit 
cell adherence.  
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Figure 4.10: Housing to Culture and Monitor Tissue 
 
4.3.1 Tubular Construct Orientation  
The decision matrices found in Appendix B and C focused on the shape of the 
cartridge. Cylindrical and flat methods to orientate the tissue constructs were considered. 
The cylindrical, design would place the constructs around the perimeter of the shape 
while in the flat design fibers would be fixed in a straight line as seen in Fig.4.11.   
 
 
 
Figure 4.11: Cartridge Shapes 
 
4.3.2 Cartridge Designs 
SolidWorks 2008 was used to make detailed drawings and 3-D representations of 
novel cartridge designs. The spacer and end cap together are referred to as a manifold. 
The housing device was attached to the rest of the assembly by screws which brought the 
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four pieces together to form the cartridge housing. The pieces were designed so that they 
could be screwed together, allowing for access to the constructs. The cartridge design 
shown in Fig. 4.12 incorporates the cylindrical formation of the grafts where the cartridge 
design in Fig. 4.13 incorporates the flat orientation of constructs. 
 
 
Figure 4.12: Cylindrical Cartridge Design 
 
Figure 4.13: Flat Cartridge Design 
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5.0 Design Verification  
In order to verify the design of the bioreactor, the three main functions were 
tested in parallel. The final design aspects that were chosen were the porous hollow fibers 
to be used as the support structure to grow the cells on. The vacuum system was chosen 
as the seeding method and the flat cartridge was chosen as the housing to monitor and 
culture the tissue. These aspects were chosen based on the decision matrices in Appendix 
C and conversations with the client. The hollow fiber mandrels allowed for vacuum 
seeding and artificial cell culture, satisfying two functions of the bioreactor. Therefore, 
the housing design was based off the size of the fibers as seen in Fig. 4.13. and 5.1. 
 
Figure 5.1: SolidWorks Cartridge 
The support structure to assemble the cells was tested by verifying that the porous 
hollow fibers (polysulfone+ FiberCell) could support cell growth and to determine a 
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method to visualize cell growth without removal from the bioreactor’s cartridge.  The cell 
assembly and culture methods were also tested and analyzed using Fluent computational 
fluid dynamics software and pump testing. The housing to culture and monitor the tissue 
was also tested using Fluent and additional visualization testing.  
 
5.1 Verification of Support Structure 
Assuming the bioreactor would be used for research purposes, growth within the 
bioreactor needed to be assessed without compromising the tissue. When observing the 
fibers using a compound microscope the fibers appear black. Therefore it was essential to 
develop a method to distinguish the polysulfone+ fibers, shown in Fig 5.2, from the HDF 
cells in order to assess cell attachment and growth. Additionally, the compatibility of 
polysulfone+ fibers with cell growth was observed. The two methods used to verify the 
support structures, the hanging drop and the v-well, which are explained in more detail in 
Section 5.1.1 and 5.1.2.  
Figure 5.2: Magnified Fibers (Hydrated and Dehydrated) 
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Human Dermal Fibroblasts (HDFs) were cultured starting at passage 12.  Cells 
were observed approximately every 24hrs, fed approximately every 48 hrs, and passaged 
when observed to be 80-100% confluent. Cells were cultured using DMEM which 
contained approximately 10% Fetal Bovine Serum (FBS) and approximately 1% Pen-
Strep. Before utilization in experiments, the number of viable cells was measured using 
Trypan Blue in order to make the specified cell concentration for experimentation. 
Trypan Blue stains dead or dying cells while viable cells are not dyed. A 1:1 solution of 
Trypan Blue and cell solution (40µL each) was made and micropipeted into a 
hemocytometer used to count the cells.  
 In order to incorporate the polysulfone+ fibers in tests and the bioreactor design 
they first needed to be removed from the FiberCell cartridge which contained 20, 10cm 
long fibers. This process was carried out in a sterile environment and with sterile tools in 
order to ensure that the fibers would not be contaminated. All materials used to open the 
cartridge were sterilized using an autoclave for 15 minutes at 121
o
C and all procedures 
were performed in a fume hood, Fig. 5.3.  
.  
Figure 5.3: Materials Used to Open FiberCell Cartridge 
A disposable sterilized towel was placed on the work surface of the fume hood to 
decrease the risk of contamination. A saw was used to remove the end-caps of the 
FiberCell cartridge and sterile surgical scissors were used to separate the polysulfone+ 
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fibers which were embedded in polyurethane. Forceps were used to place the fibers on 
the sterilized towel so that they could be cut into the specified lengths. The fibers were 
cut using a razor into ten 6cm fibers and ten 4cm fibers. The 4cm fibers were then cut in 
half resulting in twenty 2cm fibers. The fibers were placed using forceps in 15mL sterile 
centrifuge tubes in order to store them without risk of contamination. The fibers were 
separated into six different centrifuge tubes so that there were 5 fibers in each tube in 
order to further prevent contamination. 
 It was necessary to precondition the polysulfone+ fibers before they could be 
successfully used in cell culture. The preconditioning was in accordance with the 
protocols outlined in the FiberCell guide (Hollow Fiber Bioreactor User’s Manual, 2008) 
Only the 2cm fibers were statically preconditioned while the 6 cm fibers were kept for 
use in the completed bioreactor design. The fibers were soaked in ethanol, phosphate 
buffered saline (PBS), cell culture media according to the procedures outlined in Sections 
5.1.1 and 5.1.2. 
 
5.1.1 Verification Using Hanging Drop Method 
The hanging drop method is a technique utilized to promote cell adhesion to a 
tubular construct using the forces of gravity. This technique was used to determine the 
methods that would allow the best visualization of HDF attachment, confluence, 
proliferation, and viability on the polysulphone+ mandrel. Polydimethylsiloxane (PDMS) 
was mixed with 10% curing agent and poured into a cylindrical mold. A small piece of 
silicone tubing (about 1.3mm OD and 2cm length) was placed on the PDMS to form a 
grove where the polysulphone+ fibers would sit. The PDMS filled mold was placed in an 
oven at 80
o
C for 45 minutes. The cured PDMS rings were removed from the mold and 
sterilized using an autoclave. A 2cm polysulphone+ fiber was placed in the grove and 
fixed using sterile silicon glue.  
The glue was allowed to set for 30 minutes. The PDMS rings, with attached fibers 
facing up, were fixed using silicon glue in the middle of three six well plates, one per 
well until a total of 16 wells contained the PDMS ring and attached fiber. This set-up is 
shown in Fig. 5.4. 
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Figure 5.4: PDMS Ring Attached to Fiber 
Two sets of hanging drop experiments were carried out. In the first set of 
experiments, the polysulfone+ fibers were preconditioned by soaking in ethanol for 15 
minutes and soaking in cell culture media for approximately 72 hours after the six well 
plates were prepared for the hanging drop experiments as outlined above. CellTracker, a 
florescent dye, was used to label the cells to determine if the cells attached to the fibers. 
CellTracker was added to suspended cells and 3 of the 16 wells were seeded with cells 
loaded with CellTracker. Next 14 wells were seeded with a cell solution that did not 
contain CellTracker. The remaining well was used as a control and left unseeded. A 
micropipet was utilized to place a cell solution of 280μL at a concentration of 
10
6
cells/mL into the center of each PDMS ring except the control which received 280μL 
of blank cell culture media. Remaining cell solutions were plated in a 75cm
3
 cell culture 
flask. The plates were flipped and the surface tension allowed the drops of solution to 
hang without falling so that they surrounded the fibers as shown in Fig. 5.4.  
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Figure 5.5: Hanging Drop Plates 
At this point, the plates were allowed to incubate for 1hr. After cell attachment the 
plates were flipped back to their normal orientation. The remaining solution was 
aspirated and 6mL of fresh media was added to each well as shown in Fig. 5.6.  
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Figure 5.6: Media in a Hanging Drop Well 
The wells that contained cells with CellTracker solution were viewed using a 
florescent microscope after the 1 hr seeding period. The observed fibers were fluorescing 
but the control also fluoresced. The plated cells that contained CellTracker were viewed 
using the fluorescent microscope and the cells fluoresced much brighter than the fibers. 
At this point it was determined that cells had not attached onto any of the fibers that were 
seeded with the CellTracker cell solution. After 3 days CellTracker solution was added to 
3 wells seeded normally (not loaded with CellTracker).  Once again no observable 
difference could be determined when the seeded wells were compared to the controls. 
Once again it was determined that no cells had attached to these fibers. Although the 
protocol developed for this experiment outlined instructions to add CellTracker to 3 wells 
every 3 days, the experiment was stopped at this point since no cell attached was 
observed.  
The cells plated with CellTracker were observed over a 48 hour period to 
determine the effects of CellTracker on cell viability. It was observed that the cells 
loaded with CellTracker were not as healthy as unmodified cells. From these 
observations it was determined that loading the cells with CellTracker before cell seeding 
could be affecting cell attachment. The protocol for the second hanging drop experiment 
was modified based on the results of the first experiment. Furthermore, on second 
examination of the FiberCell Bioreactor guide, it was determined that in order for cell 
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attachment to occur on the polysulfone+ fiber, they must also be preconditioned with 
PBS.  
A second hanging drop experiment was therefore set up with an adapted protocol. 
For this experiment the fibers were preconditioned by soaking in ethanol for 15 minutes, 
soaking in PBS twice for 5 minutes each, and finally soaking in cell culture media for 
approximately 72hrs. For this experiment the cell culture media was changed every 24hrs 
during that portion of the preconditioning. No cells were seeded with CellTracker 
however CellTracker was planned to be added to 3 wells, 3 days after seeding the fiber. 
One day after cell seeding, fibers were viewed using a stereomicroscope and compared to 
the control which had no cells added to determine if cells had attached to the fibers. At 
this point the experiment looked promising but it could not be definitively determined 
that cells had attached to the fiber. Two days after cell seeding the plates were observed 
and certain wells were found to be contaminated. Therefore the plates were bleached and 
disposed of.  
At this point the team determined that a method with fewer variables and less risk 
of contamination should be implemented in order to verify the support structure chosen 
for the bioreactor design. It was determined that the hanging drop method could not 
generate reproducible results since it relied heavily on user manipulation. This extensive 
manipulation also increased the risk of contamination. Fig. 5.7 shows the inconsistencies 
of the hanging drop method. 
 
Figure 5.7: Inconsistency of Method 
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 As can be seen in Fig. 5.6 the well on the right did not result in a uniform hanging 
drop. Wells which resulted in insufficient hanging drops were marked so that these 
inconsistencies could be considered when analyzing the results. 
 
5.1.2 Verification Using the V-Well method 
 Since the hanging drop experiments were both unsuccessful, a different seeding 
method was necessary in order to verify the chosen support structures. Therefore, the V-
well method, developed by Shawn Carey, Jon Charest, Jason Hu, and Elizabeth Ellis 
(Carey et al, 2009) was carried out. A machined mold, developed by Carey et.al, to allow 
cell attachment around the entire diameter of a tubular construct was placed in a 100mm 
cell culture plate and PDMS with 10% curing agent was poured into the mold. The 
PDMS was cured by placing it in an oven set at 80
o
C for 1.5hrs.  
The polysulfone+ fibers used for this experiment were preconditioned in a 15mL 
centrifuge tube. First the fibers were soaked in 8mL of ethanol for 15 minutes. Next the 
fibers were soaked in PBS twice for 5 minutes each. Finally the fibers were soaked in cell 
culture media for approximately 120hrs changing the media every 24hrs. Two 2cm fibers 
were placed in each of the three wells. Two of the wells were seeded with a cell 
concentration of 1.85x10
6
cells/mL. The remaining well was left unseeded to be used as a 
control. The fibers were left in the cell solution for 1.5hrs at which point the solution was 
aspirated and replaced with fresh media as shown in Fig. 5.8. 
 
Figure 5.8: V-Well  Method 
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After three days, a 5µM concentration of CellTracker was added to each well. The 
cells were then observed using a fluorescence microscope. As observed during the 
hanging drop experiments, it was difficult to differentiate the fluorescence of the cells 
from that of the fiber. Additionally, it was difficult to observe the fiber while in the V-
wells and therefore the fibers were sacrificed from further experimentation by removing 
the cover of the plate and placing one seeded fiber and one control fiber in a 5mm cell 
culture flask filled with 6mL of cell culture media. Once again the fibers were observed 
using the fluorescence microscope and compared. Fig. 5.9 shows the unseeded (left) and 
seeded (right) fibers.  
 
Figure 5.9: Unseeded and Seeded Cell Tracker Fibers 
 Although the seeded fiber (right) seems slightly brighter and thicker than the 
unseeded fiber (left), this observation cannot be definitively quantified. The media in the 
wells was then aspirated and the fibers were trypsinized and Trypan Blue dye was used in 
conjunction with a hemocytometer in order to determine a cell count if any.  From the 
cell count it was determined that there was an average of 40,000 cells per fiber 
confirming that cells had in fact attached to the fibers.  From these results it was 
determined that a fluorescent dye would not be sufficient means of visualizing cell 
attachment or growth on the polysulfone+ fibers.  
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5.2 Verification of Cell Assembly and Culture Methods 
The cell assembly and culture methods were verified using Fluent and other 
testing methods explained in this section.  In order to verify this aspect of the bioreactor, 
the longitudinal flow, used for dynamic cell culture, and the vacuum force, used for cell 
seeding and assembly, were analyzed.  
First the longitudinal flow field used for cell culturing was verified. The flow field 
of the cartridge was modeled in 2D using Fluent as shown in Fig. 5.10. As expected, the 
velocities greatly increase when entering the fibers because of the drastic change in area. 
Therefore it is necessary to determine an appropriate pump setting (inlet velocity) which 
will not disturb the growth of tissue. 
 
Figure 5.10: Fluent 2-D 
Accordingly, this model allows a user to manipulate the inlet velocities in order to 
determine their respective fiber velocities so that an appropriate pump setting can be 
chosen. The pump flow rate was also determined based on the FiberCell manual which 
suggests flow rates of 1-4 ml/min per fiber during cell culture. The cartridge design 
proposed utilizes 5 fibers, so flow rates of 5-20 ml/min would be required to facilitate cell 
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culture in a single cartridge. Therefore this range of flow rates was tested using Fig. 5.10 
above to determine the range of fiber velocities this would create.  
The Fisher Scientific variable flow peristaltic pump model number 3389 selected 
for use in the bioreactor can produce flow rates of 4.0-600 ml/min. Flow tests using water 
were performed to verify the pump output and the actual range of flow rates achieved 
through 4 feet of 3/16
th
 inch silicon tubing were 2-480 ml/min. The 4 feet of tubing was 
used to approximate the resistance of the entire bioreactor. Since each cartridge would 
require 5-20 ml/min during culture, the chosen pump has the additional capacity to 
supply several cartridges at once, and it could also supply cartridge designs with greater 
numbers of fibers. 
The vacuum force through the wall of the fibers, used for cell seeding and 
assembly, was also verified using Fluent. Fig. 5.11 represents the flow around each fiber 
when the vacuum force is applied. The inlet velocity was set to 5x10
-6
 m/s and there was 
a negative pressure in the fibers of 5mmHg representing the vacuum force. For this 
model the inlets represent the access points where the cell solution would be injected for 
cell seeding. As expected the two ports as inlets on either side have the fastest velocity in 
comparison to the rest of the velocity vectors.  
 
Figure 5.11: Flow Around Each Fiber 
1 2 3 4 5 
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Figs. 5.12 and 5.13 depict the portion of the fibers which are directly under the 
inlet points (fibers labeled 1 and 5) Close to the inlet, there is a clear inequality of 
velocities circumferentially. However this 2D representation does not show the flow over 
the length of the fiber and therefore this extreme difference (approximately 6.8 x10
-6
 to 
1.1 x10
-6
) would not be experienced by the whole fiber. Fig. 5.12 and 5.13, depict fibers 1 
and 5, shows some turbulence around the circular mandrel however when considering the 
magnitude of the velocities the turbulence in negligible.   
 
Figure 5.12: Fiber 1  
 
Figure 5.13: Fiber 5 
Fig. 5.14, fibers 2 and 4, shows velocities which approach more circumferential 
symmetry. The inner side of the fiber, that which is opposite of the inlets, once again has 
slower velocities, but the range of magnitudes is much smaller, approximately 3x10
-6
 to 
0.5x10
-6
. The inlet flow is still influencing the overall unequal velocities, but the flow is 
slow enough that there is no turbulence around the cylindrical mandrel.  
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Figure 5.14: Fibers 2 and 4 
Finally, Fig. 5.15 showed the center fiber, fiber 3. Since it is located in the center 
of the cartridge, the flows coming in from the ports are symmetrical on both sides, 
allowing for the uniform velocities seen below.  
 
Figure 5.15: Fiber 3 
Fig. 5.15, above, depicted the ideal scenario, that cells would be drawn uniformly 
around the circumference. However, because the pores allow for the media to pass 
through, but not cells, the imbalances would fix themselves. Cells are pulled to the 
mandrel, and the suction through the pores initially holds the cells in place. This action 
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blocks those pores and the open ones will have a stronger force since the same negative 
pressure will have less inlets. Therefore, the fibers that have uneven velocity distributions 
will change as the available pores decrease.  
The above diagrams only show perspective of the flow around the fibers. It is also 
important to note the flow over the length of the fiber. Fig. 5.15 shows flow entering 
from two inlets, once again representing the access points where the cell solution is 
injection for cell seeding. As can be seen, the velocity decreases outside of the ports 
because of the change in area and spreads over the length of the fiber (shown in red). The 
same principle explained above applies here: as cells are seeded the remaining pores will 
draw the cells over the unseeded sections.  
 
Figure 5.16: Flow Through Two Inlets 
The pump was also tested to ensure that it was capable of producing flow in 
through the walls of the fibers in order to create a vacuum for cell seeding. The fibers 
chosen for use as mandrels were designed to be used in bioreactors where longitudinal 
flow through the fibers is all that is required for successful cell culture. The vacuum 
seeding of cells onto these fibers in the proposed bioreactor would require the temporary 
creation of an alternate flow during the cell-seeding period. The ability to create flow 
through the fibers was examined using a syringe pump and a pressure transducer. The 
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original Fibercell cartridge was connected to the syringe pump and a pressure transducer 
so that the pressures required to achieve flow through the walls of the fibers could be 
recorded. Flow rates of from 0.01-4.0 ml/min were achieved through each 5 cm of fiber 
with pressures of less than 5mm mercury. The actual flow rates used for vacuum seeding 
would ultimately be determined experimentally and through modeling of the flow and 
forces created at the surface of the fibers.  
 
5.3 Verification of Housing to Culture and Monitor Cells 
 The housing to culture and monitor the cells was verified using Fluent and 
visualization testing. First Fluent was used to verify that the cartridge design allowed for 
uniform flow through each fiber by modeling the flow field of the cartridge design. Fig. 
5.17 shows a 2D model of the longitudinal flow. The flow was assumed to be laminar and 
a range of velocities was tested.  
 
Figure 5.17: Flow Through Each Fiber 
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 As can be seen in Fig. 5.16 above the flow evenly distributes through each fiber 
which verifying that the cartridge design allows for uniform flow through each fiber. 
In order to verify the design of the cartridge the team needed to determine a 
cartridge width that would allow for visualization, using a microscope, of the 
polysulfone+ fibers without their removal from the cartridge. However the width of the 
cartridge was also determined based on the volume of media that could fit in it. As can be 
seen in Fig. 5.18 media, which is pumped through the fibers, does not fill the extra 
capillary space of the cartridge and therefore media must be manually injected into this 
space and manually changed based on its glucose levels.   
 
Figure 5 18: Bioreactor with Media 
Thus it is important that a sufficient volume of media is contained in the extra 
capillary space so that glucose and oxygen levels remain sufficiently high between media 
changes. The extra capillary space of the FiberCell cartridge is approximately 27 cm
3
. In 
order to decrease manual manipulation and to ease the manufacturing process, an extra 
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capillary space of approximately 41 cm
3
 was chosen. In relation to the extra capillary 
space of the Fibercell cartridges and in proportion to the number and length of fibers, this 
about 1.5 times the Fibercell volume. This resulted in a cartridge width of 1.27cm. This 
width was therefore tested under a microscope to ensure that the fibers could be put in 
focus and observed without removal from the cartridge.  
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6. 0 Final Design and Validation  
 The construction of the prototype and testing was essential to begin to determine 
whether or not the design choice met all of the objectives and could be used to produce 
small-diameter vascular grafts. The following sections describe in detail the construction 
and verification of the bioreactor design choices. All materials used are listed in 
Appendix E, including prices, details of what was purchased and the company the 
products were purchased from. 
 
6.1 Construction of the Bioreactor 
The components of the bioreactor, pictured in Fig. 6.1, were obtained and 
connected using silicone tubing. Each component contributed to the function of the whole 
bioreactor, a media reservoir, a pump to move the fluid, a gas exchange tubing coil, and 
the cartridge to house the fibers and allow cell seeding and culture.  
 
Figure 6.1: Completed Bioreactor 
The CAD file for the cartridge was imported into GibbsCAM software in order to 
generate the CNC code required to machine the polycarbonate components of the 
cartridge.  The tool choices, tool paths, and fixturing strategies were all discussed and 
planned with the aid of Neil Whitehouse, who runs the shop at WPI.  The majority of the 
fabrication was done in the machine shop at WPI and the remaining fabrication was 
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completed in the MQP lab. The overall dimensioning of the thicker components was 
performed on manual mills and the thinner components were done completely on the 
CNC machine. 
Once all the polycarbonate pieces were machined, a belt sander was used to 
correct edges that were not completely surfaced by the CNC machine, due to the thinner 
pieces falling out of the tool path before the last few centimeters were cut. A razor blade 
and knife were used to remove excess material from all edges and holes. Enough parts to 
assemble two complete cartridges were machined so that if any parts were damaged 
during fabrication there were spare parts to be used. As no parts were damaged during 
fabrication, two cartridges were assembled. Each cartridge fabricated consisted of two 
end caps and spacers (which together created a manifold). Fig. 6.2 and 6.3 show a spacer 
with holes for the ends of the hollow fiber mandrels in the center leaning against the 
cartridge housing, and the end cap to the right. Two 5.1 x 7.6 x 0.6 cm thick pieces made 
up the front and back of the cartridge housing and two 5.1 cm long T shaped blocks made 
up the top and bottom of the housing. The two access ports in each top and bottom T 
block and one port in each end cap were drilled and tapped for 10-32 threaded luer 
fittings. 
 
Figure 6.2: Disassembled Cartridge 
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Figure 6.3: Assembled Cartridge 
The hardware used to fasten the cartridge components together consisted of 
stainless steel 8-32 button head screws and 3/32 stainless steel dowel pins. The holes 
were tapped by hand and then the cartridges were test assembled to verify fitment of all 
components. The access ports were fitted with 10-32 luer fittings and then 4-way 
polycarbonate luer valves were attached to each fitting (Fig. 6.4). 
 
Figure 6.4:Cartridge with Luer Fittings 
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The two media reservoirs were created by drilling two holes in the caps of  500 ml 
pyrex bottles and inserting two 3/16
th
 pieces of stainless steel tubing through the holes. 
The tubing was bent with a small hand held tubing bender to facilitate silicon tubing 
attachment and to reduce bending of silicon tubing when connected to the entire 
bioreactor (Fig. 6.5).  
 
Figure 6.5: Media Reservoir 
            A platform was then fabricated that would hold all the components of the 
bioreactor together so that the entire assembly could be moved easily in and out of the 
incubator and flow hood. Fig. 6.1 incorporated the main components of the bioreactor 
and was attached with silicon tubing.  
 
6.2 Validation of Final Design 
In order to validate that the final design of the bioreactor worked as it was 
intended, flow testing using colored dye and Fluent was used to verify the final design, as 
described in Chapter 5.0. 
 
6.2.1 Flow Testing Using Colored Dye               
                      The bioreactor was tested in both the longitudinal flow path and in the 
vacuum seeding flow path with colored dye, to visually verify flow. The reservoir was 
filled with red dye and the valves were first adjusted to the settings required for 
longitudinal flow. The pump was set to the priming speed setting and red dye was drawn 
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out of the reservoir, through the gas exchange coil, longitudinally through the fibers and 
cartridge, through the pump, and back into the reservoir as in Fig. 6.6. The bioreactor 
functioned as expected in the longitudinal flow path and the red dye allowed a quick and 
simple qualitative verification of this. 
 
Figure 6.6: Dye Simulation of Longitudinal Flow Path 
 The vacuum seeding flow path was tested next, for which blue dye was used. The 
valves were adjusted to the settings for vacuum seeding, but instead of having flow into 
the cartridge through two ports, one port was tested at a time. The red dye from the first 
test was still present in the tubing and reservoir, but had not yet diffused through the 
fibers into the extra capillary space, which remained clear.  A syringe with blue dye to 
simulate the cell solution that would be injected into the cartridge during vacuum seeding 
was connected to one of the luer valves on the cartridge. At the same time, another empty 
syringe was connected to the valve diagonally opposite as seen in Fig. 6.7.   
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Figure 6.7: Cell Seeding Using Dye Simulation 
 
The pump was turned on at the same time the syringe with blue dye was injected, 
slowly, into the cartridge. The red dye was seen coming in the lower port on the cartridge 
and the blue dye, simulating the cell solution, was seen coming in the opposite port, Fig. 
6.8. The other syringe was slowly expanded to absorb the fluid displaced by the blue dye 
solution which was being injected into the extra capillary space.  The valves were then 
adjusted so that the other port into the cartridge could be tested. The tests showed that the 
vacuum seeding pathways of the bioreactor also performed as expected.  The blue dye 
representing the cell solution was also injected into the cartridge and drawn in through 
the walls of the fibers, and then out the end cap/manifold of the cartridge.                  
 
Figure 6.8: Vacuum Seeding Flow Path 
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7.0 Discussion  
 Each chosen aspect to fulfill the bioreactor functions are discussed in this chapter.  
The way the chosen design affects outside factors is also discussed briefly in this chapter 
to better understand the impact of it. 
 
7.1 Bioreactor Design 
The cartridge was fabricated with less than five dollars worth of polycarbonate 
and stainless steel hardware. Six hours of CNC machine time was required to make all 
the components for a single cartridge, mostly due to set up and part fixturing. This could 
be reduced to well under an hour if done by professional machinists and dedicated 
fixtures were designed for each component.  
 
7.1.1 Mandrel Choice 
The polysulfone fibers chosen for use as mandrels demonstrated excellent flow 
characteristics when evaluated for vacuum cell seeding suitability. The pressures required 
to achieve relatively high flow rates through the fiber walls were found to be less than 
5mmHg. It is likely that the ultimate flow rates determined through experimentation to be 
appropriate for cell seeding will produce pressures of much less than this. Tests were 
completed to verify even pore distribution, by forcing air out through the walls of the 
fibers, while submerged in water, which resulted in uniform distribution of pores across 
the fibers surface. This validates that uniform vacuum seeding of the grafts should occur 
due to even pore distribution on the surface of the fibers. 
 
7.1.2 Cartridge Shape 
The cartridge shape did ultimately allow for visualization of all fibers through a 
light microscope from a single perspective. The challenge that remains is finding an 
appropriate means to access cell growth on the fibers during culture. The fibers exhibited 
a moderate degree of auto-fluorescence; however software could allow the baseline 
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fluorescence to be removed so that a measurable signal from the cells could be viewed. 
Once an appropriate cell tracking technology is found, the cartridge shape will allow for 
easy monitoring of the grafts during culture due to the linear fiber array, the flat faces of 
the cartridge, and the excellent optical clarity of the polycarbonate.  
 
7.1.3 Vacuum and Cell Seeding 
In general, when cells attach to the fibers, the pores that attracted those cells will 
be covered, leaving the uncovered pores more able to attract cells. This way even with 
uneven distribution over the fiber circumference, complete coverage is possible. 
Cell seeding of the cartridge will be done using Fibercells recommendations of 
inoculating enough cells to achieve 50% coverage of the fibers assuming a 60-80% 
attachment rate. This would amount to 1-2 million cells per cartridge, since each 
cartridge has 5 fibers with total fiber surface area of 12.3 square centimeters. 
Future research will focus on characterization of the fibers with SEM so that the 
forces experienced by the cells at the surface of the fiber during vacuum seeding can be 
more accurately modeled.  These models will be correlated with experimental outcomes 
resulting from seeding and culturing the grafts so that optimized cell seeding protocols 
can be developed. From these models and experiments new insights into cellular 
responses to mechanical forces will be gained. 
 
7.2 Economic Impact 
If the bioreactor were ultimately successful in generating vascular grafts that 
could gain FDA approval for clinical use, the economic impact could be tremendous. The 
money saved by avoiding the harvest of autologus vessels, and treating the complications 
associated with synthetic grafts, would likely more than offset the costs of generating the 
tissue engineered vascular grafts. 
The production of this device would also affect those researchers interested in 
cardiovascular disease and could reduce or eliminate the need to sacrifice animals for the 
advancement of their research.  The bioreactor can be used as an ex-vivo vascular model 
by co-culturing SMCs with an endothelial monolayer. In this way a cost effective model 
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using human cells could be easily and readily available to further research into 
cardiovascular disease. 
There are also potential applications in all of tissue engineering, since the 
artificial capillary cell culture techniques used here to produce the vascular grafts could 
be applied to other tissues as well. The tissue engineered vascular grafts themselves could 
be used in order to vascularize other tissue engineered tissues or organs as they are 
cultured, or when implanted into patients.  
 
7.3 Environmental Impact 
If this device were used in clinical applications, the cartridge would most likely be 
replaced for each patient due to the lower cost of replacing the polycarbonate cartridge 
versus the labor to resterilize the components. The minimal labor required to resterilize 
the cartridge however, would allow an environmentally conscious company to reuse the 
cartridges with little increase in overall production costs.  
 
7.4 Societal Influence 
The successful production of tissue engineered vascular grafts could benefit a large 
cross section of society, both in quality and quantity of life.  Patients suffering from 
cardiovascular disease would be able to use their own cells to produce tissue that could 
replace their diseased vascular tissue.  One in four deaths is caused by cardiovascular 
disease and having this option could save many lives. 
 
7.5 Political Ramifications 
Many countries believe that tissue engineering is not socially acceptable.  
Producing a bioreactor that can grow tissue is looked down upon by many religions.  
Although some countries would be against the use of this device, it could benefit many 
patients and researchers around the world. 
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7.6 Ethical Concern 
With most tissue engineering advances, there are ethical concerns involved.  
Although a replacement blood vessel has the potential to save many lives, some feel that 
growing tissue is not acceptable.  While there are options, the device would make it 
easier and cause fewer complications than options available today. 
 
7.7 Health and Safety Issues 
The device has the potential to improve the health of patients suffering from 
cardiovascular disease and is an alternative to methods that have been shown to cause 
side effects.  Replacing diseased tissue can be done by harvesting blood vessels from 
other parts of the body which requires multiple surgeries and often leads to suffering 
where the tissue was harvested from.  Synthetic grafts often lead to compliance mismatch 
and cause thrombosis.  Currently, the method of growing tissue is time consuming, which 
may be more time than the patient might have.  Replacing diseased tissue with tissue 
engineered vessels made from the patient’s own cells decreases the risk of immune 
rejection that may result from using donor tissue. 
 
7.8 Manufacturability 
The device could be mass produced using the specifications and machining files 
that were developed.  The device was designed with reproducibility in mind in that it is 
inexpensive and easy to manufacture.   Cell harvesting and tissue growth would have to 
be done by a professional but with proper use of the device; the tissue would be easily 
produced.  If the device were used to produce vascular grafts to be implanted in the body, 
a new cartridge could be used for each patient.  Using the same set-up of the bioreactor 
with each patient would allow the user to only replace the cartridge, thereby eliminating 
steps from the process. 
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7.9 Sustainability 
Although this device does not directly use energy, it requires the use of an 
incubator and vacuum pump.  Growing tissue would require more energy than 
conventional methods of harvesting tissue from donors.  The device could easily be used 
in an incubator that is environmentally friendly and vacuum source that uses less energy.  
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8.0 Conclusions and Recommendations  
Although time constraints prevented tissue culture using the final bioreactor 
design, each aspect of the bioreactor was validated: the polysulfone+ fibers used as a 
structure to support cell growth, the pump and vacuum used for cell culture and seeding, 
and the cartridge design used to house and monitor cell growth. This provides a proof-of-
concept suggesting that the bioreactor could be used to generate vascular grafts.   
 
8.1 Design Choice 
The design of a novel bioreactor which allows cells to self assemble into tubular 
constructs was accomplished. The vacuum and flow patterns shown in Fluent, in 
conjunction with testing of the fibers, leads to the conclusion that cells could assemble 
uniformly around the mandrels. The bioreactor design is also beneficial because it allows 
for changes in fiber diameter and number based on the application. Additionally the 
bioreactor allows for a sterile environment where mechanical conditioning and testing 
can be performed in the future. This could be done in the case that a degradable mandrel 
is used, as the pump system could be used at different pressures through the vessels. 
Ultimately the design must be validated by seeding the cartridge with cells.   
 
8.2 Future Recommendations 
The team recommends that a method to visualize cell growth on the fibers should 
be a focus of future studies. The flow field of the cartridge should be modeled in 3D 
using Fluent in order to completely analyze the fluid dynamics of the cartridge. Cells 
should also be modeled in the cartridge using Fluent to determine how the vacuum force 
would affect the cells. The cartridge design could be further optimized to ease 
manufacturing and combine cartridge parts so there is less chance of leakage.  
 The fiber could be changed to find ideal porosities for culture and vacuum 
seeding or could be manufactured based on desired specification using electrospinning. A 
fiber material that degrades over a specified period of time would be ideal eliminating 
64 
any vascular graft manipulation. Additionally, a degradable mandrel would more easily 
allow resulting vascular grafts to be tested without removal from the cartridge. The 
development and manufacture of this new mandrel would in itself be a huge undertaking, 
requiring investigation of different polymers and degradation rates that allow for enough 
ECM production before the support disappears.  
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Glossary 
Anastomosis – the connection between vascular structures. 
Autologous – transplanted tissue from the same patient. 
Coronary Artery Bypass Graft – Surgery performed to correct arterial blockages in the 
heart by implanting a graft, restoring flow distal to the blockage. 
Coronary Heart Disease – Conditions affecting the vasculature in the heart. 
Electrospun – the production of micro- or nano-scale fibers with electrical charges. 
Exogenous scaffolds – an externally produced structure for tissue culture to incorporate 
into. 
Graft – a transplanted vessel. 
Hemocytometer – a device that counts cells. 
Hemodynamic loading – the forces against a vessel from blood movement. 
Human Dermal Fibroblasts – cells derived from the dermis of a human, can be obtained 
by skin biopsy. 
In Vitro – experimentation within a controlled environment. 
In Vivo – experimentation within a living organism. 
Internal Mammary Artery – also known as the internal thoracic artery, supplying blood to 
the anterior chest wall and breasts.  
Mandrel – a structure used for shaping. 
Media – also known as cell culture media, is a liquid or gel designed to support cell 
growth. 
Myocardial Infarction – commonly known as a heart attack, occurs when blood flow in 
the heart is interrupted.  
Polysulfone+ – a thermoplastic polymer that allows for proteins to bond. 
Saphenous Vein – vein located in the superficial posterior leg. 
Smooth Muscle Cells – involuntary, non-striated muscle cells. 
Thrombosis – the development of a blood clot within a vessel. 
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Appendixes 
APPENDIX A: Pairwise Comparison Charts 
        
BIOREACTO
R 
Continuous 
nutrient 
delivery 
Outputs 
tubular 
construct 
Easy 
to use 
Low 
cost 
Safe for 
user 
Fast 
result 
times 
Multiple 
cultures 
SCOR
E Weight Percent 
Continuous 
nutrient 
delivery   0 0.5 1 0 0 0.5 2 0.103 10.26 
Outputs tubular 
construct 1   1 1 0 1 1 5 0.256 25.64 
Easy to use 1 0   1 0 0 1 3 0.154 15.38 
Low cost 0 0 0   0 0 0 0 0.000 0.00 
Safe for user 1 1 1 1   1 1 6 0.308 30.77 
Fast graft 
generation 1 0 0.5 1 0   1 3.5 0.179 17.95 
Multiple 
cultures 0 0 0 0 0 0   0 0.000 0.00 
 
Vascular Grafts 
VASCULAR 
GRAFTS 
Suturable 
Easy to 
handle 
High 
burst 
pressure 
Self 
generated 
ECM 
Fast 
growth 
rates Reproducible Biocompatible SCORE Weight Percent 
Suturable   1 0 0 0 0 1 2 0.100 10.00 
Easy to 
handle 0   1 0 0 0 1 2 0.100 10.00 
Appropriate 
burst 
pressures 1 0   0 0 0 0.5 1.5 0.075 7.50 
Self generated 
ECM 1 1 1   0.5 0.5 1 5 0.250 25.00 
Fast growth 
rates 1 1 1 0   0 1 4 0.200 20.00 
Reproducible 1 1 1 0 0.5   1 4.5 0.225 22.50 
Biocompatible 1 0 0 0 0 0   1 0.050 5.00 
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APPENDIX B: Functions/Means Morphological Chart 
 
Functions Means       
Creates/Supports  
tubular construct 
Mechanical Mandrel Tubular Dye Tubular Mandrel 
Negative 
Space 
Mold 
Allow removal of 
intact tubular 
construct 
Mechanical Mandrel 
Material 
Properties 
Material Coatings 
Chemical 
Solutions 
Facilitate cell 
seeding 
Pump/ Vacuum 
Material 
Properties 
Material Coatings Rotation 
Promote cellular 
growth 
Pump/ Vacuum 
Nutrient 
Permeable 
Materials 
Media Composition 
Growth 
Factors 
Promote cell 
adhesion 
Pump/ Vacuum 
Material 
Properties 
Material Coatings Rotation 
Allow nutrient 
diffusion/ gas 
exchange 
Pump/ Vacuum 
Permeable 
Materials  
Rotation 
Allow for 
visualization of 
fibers 
fibers around perimeter of 
housing 
flat housing 
(fibers in line) 
clear housing 
 
Housing for fibers cylindrical rectangular flat 
 
Fixation of Fibers o-rings silicone sealant 
  
Vacuum adheres 
cells to mandrel 
pump flow from outside 
surface of mandrel to inside 
surface 
   
Closed off housing reverse threaded cap clamped cap pop off cap 
 
Fibers are easily 
removed 
reverse threaded cap 
both ends are not 
permanently 
fixed 
one end of housing 
permanently fixed/ one 
not 
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APPENDIX C: Decision Matrixes  
Mandrel Type 
Decision Matrix         
  
Mechanical 
Mandrel 
Tubular 
Dye 
Tubular 
Mandrel 
Negative Space 
Mold 
Objectives     
Reproducible 2 2 2 2 
Tubular Vascular Graft 2 2 2 2 
Multiple Cultures 2 2 2 2 
Fast production time 2 2 2 2 
Low cost 0 2 2 1 
Easy to use 1 2 2 1 
Constraints     
Time 1 2 2 2 
Budget 0 2 2 2 
No exogenous scaffold 2 2 2 2 
Fits in incubator 2 2 2 2 
Sterilizable 2 2 2 2 
Functions     
Creates/Supports tubular 
construct 2 2 2 2 
Facilitate cell seeding 1 2 1 2 
Promote cellular growth 1 2 2 1 
Promote cell adhesion 1 1 1 2 
Allow removal of intact tubular 
construct 2 1 1 1 
Allow nutrient diffusion/gas 
exchange 1 2 2 1 
Total 24 32 31 29 
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Cell Seeding Method  
 
Decision Matrix       
  Manual Pump/Vacuum Rotation 
Objectives    
Reproducible 1 2 2 
Tubular Vascular Graft 1 2 2 
Multiple Cultures 2 2 2 
Fast production time 1 2 2 
Low cost 2 1 1 
Easy to use 0 2 2 
Constraints    
Time 1 2 2 
Budget 2 1 1 
No exogenous scaffold 2 2 2 
Fits in incubator 2 2 2 
Sterilizable 2 1 1 
Functions    
Creates/Supports tubular construct 1 2 2 
Facilitate cell seeding 0 2 2 
Promote cellular growth 0 2 2 
Promote cell adhesion 0 2 0 
Allow removal of intact tubular construct 2 2 2 
Allow nutrient diffusion/gas exchange 1 2 2 
Total 20 31 29 
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Cartridge Shape  
 
Decision Matrix: Cartridge 
Shape         
  Cylindrical Rectangular Flat Triangular 
Objectives         
Fibers can be easily removed/ installed 2 2 2 2 
Cells are seeded directly into cartridge 2 2 2 2 
Easy removal of unattached cells 2 2 2 2 
Fits 12 fibers 2 2 1 2 
Functions         
Allow for visualization of fibers 0 2 2 2 
Housing for fibers 2 2 2 2 
Housing should be closed 2 2 2 2 
Fixation of fibers 2 2 2 2 
Vacuum adheres cells to mandrel 2 2 2 2 
Facilitate cell dispersion during seeding 2 2 0 2 
Constraints         
No cell adherence 2 2 2 2 
Total 20 22 19 22 
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 APPENDIX D: Protocols 
 
Harvest of Fibers from Cartridge 
 
Materials-  Steel hacksaw blade 
                   Surgical scissors 
                   Sterilizable containers for fibers (10-20) 
                   (Aluminum foil?) 
                   steel probe/large sewing needle (open fiber end after cutting with scissors) 
                   Lengths of stainless steel welding rod to gauge fiber lengths to cut 
                   Labels for fiber lengths/numbers in each container 
                   Tape/caps to cover fittings after removal of cartridge 
                   Stainless steel welding rods cut for use as length gauges 
                   2 Male luer lock plugs 
1.)  sterilize containers, scissors, saw blade, welding rod, probe/needle, razor blades,  
2.) Place all sterilized materials in hood.  
3.) Open fiber cell cartridge assembly bag in hood and remove cartridge by unscrewing 
luer lock fittings at each end and immediately plug each luer lock with sterile male plugs. 
Place assembly minus cartridge back in bag and reseal with tape. 
4.) Cut off each end of cartridge flush with inside of edge of urethane end disk with either 
saw blade or razor blade (razor blade will reduce risk of particles on fibers). 
5.) Cut fibers in half, then cut halfs into shorter lengths for testing if required. Use 
welding rod gauges to aid in cutting to required lengths. Use probe/needle to verify that 
ends of fibers are fully open and round. 
6.) Place fibers in containers in groups appropriate for experimental method so that all 
fibers in each container will be used at the same time. 
7.) Close/seal containers and label for storage. 
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Video Camera resolution/suitability test 
 
Materials: Hi-def Video camera 
Tripod 
Scale drawing of vascular graft dimensions and wall thickness. 
 
Procedure: 
1.) test focal range and resolution of camera by filming scale drawing as 
close as possible. 
 
2.) evaluate image, crop, magnify, down convert .  
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Polycarbonate Optics tests 
 
Materials: 
Different thickness polycarbonate sheets 
Microscope 
camera 
video camera 
fiber 
 
Purpose: Establish thickness that can be used for viewing  
Procedure:  Position fiber at multiple distances away from microscope and subjectively 
decide what the furthest distance the finer can be from the base of the microscope and 
still be visible.  These steps should be repeated with the camera and video camera. 
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Bioreactor 
 
Materials:  media bottle 
Reservoir 
 cap  
Luer locks/fittings that match fibercell components 
Syringes as described in fibercell protocol 
Tubing of equal size to fiber cell set up 
Tubing for pump compression zone 
 
Procedure: 
1. Drill two .3 inch holes in cap of an autoclavable media. 
2.  Using silicone glue, glue 0.25 ID tubing to each of the holes. 
a. One tube will directly attached to the pump 
b. One tube will be the outlet of the cartridge 
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Using Trypan Blue for Cell Count 
1. Add 40µL of Trypan Blue to  
 
 
Preparation of the CellTracker 
1. Allow CellTracker to warm to room temperature which was stored below 21oC. 
2. Dissolve with DMSO to concentration of 10mM. When dissolving 1 mg of 
product with a 464.86 MW: 
0.001g x (1mole/464.86g) = 2.1512 x 10
-6
 mole 
0.01m/L= (2.1512 x 10
-6 
m/ x L) 
X= 0.000215L = 215 µL of DMSO added to CellTracker* 
3. Remove 10 µL of the working solution and place in 15mL centrifuge tube. 
4.  Dilute the stock solution to a working solution with a concentration of 5µM by 
adding 20mL of serum free media to the 50mL tube. 
(5mM)(0.01mL)= (0.005mM)(x) 
x = 20mL (allows for ~20 aliquots of CellTracker) 
(if adding 10µL then 20mL of serum free media should be added- allows for ~20) 
aliquots) 
5. Warm the working solution to 37oC. 
 
*Step 2 was only performed once to create a stock solution of cell tracker. For each 
experiment involving CellTracker, the stock solution was warmed to room temperature 
and a working solution was made as explained in Steps 3-5. 
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Hanging Drop Experiment 1 
Prepare 3 six well plates to be seeded using the hanging drop method as described in 
Section 5.1.1. Seed 13 wells with 280µL of a 10
6
 cell/mL media solution. One well 
will be used as a control.  Seed three with the following protocol: 
1. Using hemocytometer determine a cell count. Based on cell count prepare a cell 
solution of 10
6
cells/mL concentration. This way once the CellTracker is added it 
will be easy to resuspend the cells in the correct amount of fresh media without 
recounting 
2.  Centrifuge cells and aspirate remaining media 
3.  Resuspend cells in CellTracker working solution (refer to Preparation of 
CellTracker) 
4.  Incubate for 15-45 minutes 
5. Centrifuge cells 
6. Replace working solution with fresh media (same amount added to prepare 
10
6
cells/mL concentration) 
7. Incubate for 30 minutes 
8. Resuspend cells 
9. Add cell solution to 3 prepared hanging drop wells   
10. Observe after 1hr and after 24 hrs 
 
Every three days add CellTracker solution to 3 wells so that it is added to the last 
plates at day 15 using the following protocol: 
1. Remove media 
2. Add CellTracker working solution 
3. Incubate cells for 15-45 minutes 
4. Replace working solution with fresh media 
5. Incubate cells for 30 minutes 
6. Observe fibers immediately 
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Hanging Drop Experiment 2 
1. Prepare 3 six well plates to be seeded using the hanging drop method as described 
in Section 5.1.1.  
2. Seed 15 wells with 280µL of a 106 cell/mL media solution. The remaining well is 
used as a control but media should be added and changed as done with seeded 
wells. 
3. After three days of culture, add CellTracker solution to 3 wells using the 
following protocol: 
a. Remove media 
b. Add CellTracker working solution 
c. Incubate cells for 15-45 minutes 
d. Replace working solution with fresh media 
e. Incubate cells for 30 minutes 
f. Observe fibers immediately 
4. Continue adding CellTracker every three days until all wells have had 
CellTracker added to them using the protocol in Step 3.  
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V-Well Experiment 
1. Prepare PDMS V-well as described in Section 5.1.2 
2. Place six 2cm preconditioned polysulfone+ fibers in the wells (2 fibers in each 
well) 
3. Add 1mL of 1.85x106 cells/mL concentration cell solution to each well 
4. Allow the cells to seed onto the fibers for 1 hr 
5. Aspirate remaining cell solution and add fresh media 
6. After three day of cell culture add CellTracker working solution using the 
following protocol: 
a. Remove media 
b. Add CellTracker working solution 
c. Incubate cells for 15-45 minutes 
d. Replace working solution with fresh media 
e. Incubate cells for 30 minutes 
f. Observe fibers immediately 
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Cartridge Seeding Protocol 
A. Preparation of Bioreactor  
a. Close the inlet and outlet of the cartridge to isolate it from the flow path. 
b. Flush ethanol through the cartridge for at least 1 minute using the syringes 
connected to the access points on the cartridge. 
c. Flush it with PBS twice. 
d. Open the inlet and outlet of the cartridge. 
e. Pump media through the bioreactor until the system is filled.  
f. Tilt the bioreactor to remove air bubbles and check for leaks.  
g. Close the inlet and outlet of the cartridge to isolate it from the flow path. 
Ensure that there are no air bubbles or leaks in the cartridge.  
h. Pump the media through the system for 1minute at maximum speed, check 
for leaks. 
i. Incubate the bioreactor filled with media for three days changing the 
media and pumping the media through every 24hrs. 
j. Before seeding, change the media.  
B.  Preparation of cells 
a. Trypsinize 80% confluent HDFs from two, 75cm2 cell culture flasks and 
centrifuge. 
b. Aspirate media. 
c. Resuspend cells in fresh media and get cell count using a hemocytometer.  
d. Prepare a cell solution of 1.5 X106 in 5 mL of media.  
C. Seeding the bioreactor  
a. Isolate the cartridge from the flow path and add the cell solution using a 
syringe through one access point. A syringe is connected to the other 
access point. Both syringes will be used to flush the cell solution back and 
forth to ensure a uniform cell suspension throughout the cartridge. 
b. Ensure that the excess cell solution is distributed evenly between the 
syringes.  
c. Close one syringe access point and open one side of the cartridge. 
d. Add the remaining cell solution from that syringe. 
e. Repeat for the other syringe.  
f. Change from longitudinal flow path to vacuum flow path. 
g. Vacuum Seed for 2 hours. 
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APPENDIX E: Bill of Materials 
Plastics Unimited Inc.  
http://www.plasticsunlimitedinc.com/ 
Product Details 
Polycarbonate sheet 1"thick 
Polycarbonate sheet 1/4" thick 
Polycarbonate sheet 1/8" thick 
drop offs/random size pieces $6.00  
 
Small Parts Inc.  
http://www.smallparts.com 
Part Number Units Details Cost 
XPHP-0632-12-50   50 / pack   3/4 inches  (316 6-32 ssteel screws) $3.11  
XPHP-0632-16-50   50 / pack   1 inches   (316 6-32 ssteel screws) $3.49  
PPHX-0632036-25   25 / pack   1 1/2 inches  (316 6-32 ssteel screws) $3.26  
DWXX-021-10    10 / pack   (ssteel 3/16 dowel pins) $7.40  
A1-LXM021   10 / pack   ( M luer to 10-32) $5.40  
B1-LXF018   10 / pack   (F luer to 10-32) $4.50  
FTLL250-6   25 / pack   (F leur to 3/16 barb) $6.67  
MTLL250-6        25 / pack   ( M leur to 3/16 barb) $7.50  
 
Factor II Inc. 
http://www.factor2.com/ 
Product # Details Cost 
A-100-S Type A Medical Adhesive Sterile $19.95  
 
Harvard Apparatus 
http://www.harvardapparatus.com 
Product # Details Cost 
722635 3-Way, FLL to MLL with Port Covers (50) $121.00  
 
FiberCell Systems Inc. 
http://www.fibercellsystems.com 
Product # Details Cost 
4300-C2025   Small Polysulfone Plus Cartridge 0.1µm   $188.50  
 
 
